8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 20, 2016

Nuo Therapeutics, Inc.

(Exact name of Registrant as Specified in Charter)

Delaware	001-32518	23-3011702
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

207A Perry Parkway, Suite 1, Gaithersburg, MD 20877

(Address of Principal Executive Offices) (Zip Code)

(240) 499-2680

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

As previously reported on a Form 8-K filed by Nuo Therapeutics, Inc. (the “Company”), on January 26, 2016, the Company filed a voluntary petition in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) seeking relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”), which is being administered under the caption “In re: Nuo Therapeutics, Inc.”, Case No. 16-10192 (MFW) (the “Chapter 11 Case”). On April 20, 2016, the Company filed its unaudited Monthly Operating Report for the period between March 1 and March 31, 2016 (the "Monthly Operating Report") with the Bankruptcy Court. The financial statements in the Monthly Operating Report were not audited and were not prepared in accordance with accounting principles generally accepted in the United States. The Company cautions investors and potential investors not to place undue reliance upon the information contained in the Monthly Operating Report, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company. The Monthly Operating Report has been prepared solely for the purpose of complying with the Operating Guidelines and Reporting Requirements for Debtors in Possession and Trustees established by the Office of the United States Trustee in accordance with 28 U.S.C. § 586(a)(3). The Monthly Operating Report is limited in scope and only covers a limited time period.

There can be no assurance that, from the perspective of an investor or potential investor in the Company’s securities, the Monthly Operating Report is complete. The Monthly Operating Report may be subject to future adjustment and reconciliation. The Monthly Operating Report also contains information for periods which are shorter or otherwise different from those required in the Company’s reports pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and such information might not be indicative of the Company’s financial condition or operating results for the period that would be reflected in the Company’s financial statements or in its reports pursuant to the Exchange Act. The information set forth in the Monthly Operating Report should not be viewed as indicative of future results

A copy of this Monthly Operating Report is attached as Exhibit 99.1 hereto and incorporated herein by reference. The Monthly Operating Report annexed as Exhibit 99.1 hereto shall not be deemed an admission as to the materiality of any information disclosed therein.

The Company cautions that trading in the Company’s securities during the pendency of the Chapter 11 Case is highly speculative, extremely risky and likely to lead to financial loss. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders of the Company’s securities in the Chapter 11 Case. Accordingly, the Company discourages trading of its equity securities during the pendency of the Chapter 11 Case.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations, estimates, forecasts, and projections as well as the current beliefs and assumptions of the Company’s management. When used in this document, the words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “may,” “predict,” “will,” “would,” “could,” “should,” “target” and similar expressions are forward-looking statements. All statements contained in this Current Report that are not statements of historical fact and other estimates, projections, future trends and the outcome of events that have not yet occurred referenced in this Form 8-K should be considered forward-looking statements. Although the Company believes that its expectations reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Important factors that could cause actual results to differ from these forward-looking statements include the ability of the Company to continue as a going concern; the Company's ability to have its Chapter 11 plan approved; the Company's ability to execute upon its Chapter 11 plan; the Company’s ability to obtain Bankruptcy Court approval with respect to its Chapter 11 plan or motions in the Chapter 11 Case; the ability of the Company and its subsidiaries to prosecute, develop and consummate one or more plans of reorganization with respect to the Chapter 11 Case; Bankruptcy Court rulings in the Chapter 11 Case and the outcome of the cases in general; the length of time the Company will operate under the Chapter 11 Case; risks associated with third party motions in the Chapter 11 Case, which may interfere with the Company’s ability to develop and consummate one or more plans of reorganization (including its Chapter 11 plan) once such plans are developed; the potential adverse effects of the Chapter 11 proceedings on the Company’s liquidity, results of operations or business prospects; whether the Company will be able to identify potential third parties interested in acquiring its assets; the ability to execute the Company’s business and restructuring plan; increased legal costs related to the Chapter 11 Case and other litigation; the Company's ability to raise sufficient proceeds from the sale of assets; the Company’s ability to generate or raise cash and maintain a cash balance sufficient to fund continued capital needs; restructuring payments and debt-service; the substantial risk that the Company's common stock retains little or no value; the Company’s ability to maintain contracts that are critical to its operation; to obtain and maintain service providers; to retain key executives and employees; and other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission its most recent Reports on Forms 10-K and 10-Q. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements, and the Company's business, results of operations, financial condition and cash flows may be materially and adversely affected. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. Except to the extent required by applicable law or rules, the Company undertakes no obligation and does not intend to update, revise or otherwise publicly release any revisions to its forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events.

Limitation on Incorporation by Reference

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 is being furnished for informational purposes only and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing. The filing of this Form 8-K shall not be deemed an admission as to the materiality of any information herein that is required to be disclosed solely by Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

EXHIBIT NUMBER	DESCRIPTION
99.1	Monthly Operating report for the period between March 1 and March 31, 2016, filed with the United States Bankruptcy Court for the District of Delaware on April 20, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Nuo Therapeutics, Inc.
By:	/s/ David E. Jorden
	David E. Jorden
	Acting Chief Executive Officer & Acting Chief Financial Officer

Date: April 21, 2016

EX-99.1

Exhibit 99.1

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MONTHLY OPERATING REPORT ^*

Required Documents	Form No.	Document Attached	Explanation Attached	Affidavit or Supplement Attached
Schedule of Cash Receipts and Disbursements	MOR-1	ü
Bank Reconciliation (or copies of debtor's bank reconciliations)	MOR-1a	ü		ü
Schedule of Professional Fees Paid	MOR-1b	ü
Copies of bank statements				ü
Cash disbursements journals				ü
Statement of Operations	MOR-2	ü		ü
Balance Sheet	MOR-3	ü
Status of Postpetition Taxes	MOR-4	ü		ü
Copies of IRS Form 6123 or payment receipt				ü
Copies of tax returns filed during reporting period				ü
Summary of Unpaid Postpetition Debts	MOR-4	ü
Listing of aged accounts payable	MOR-4		ü
Accounts Receivable Reconciliation and Aging	MOR-5	ü
Debtor Questionnaire	MOR-5	ü

I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief.

/s/ David E. Jorden	April 20, 2016
Signature of authorized individual	Date

David E. Jorden	Acting CEO and Acting CFO
Printed name of authorized individual	Title of authorized individual

* The information contained herein is provided as required by the Office of the United States Trustee. This Monthly Operating Report has been prepared based on information available to the Debtor as of the ending date in the reporting period shown above, and such information may be incomplete in certain respects. All information contained herein is unaudited and subject to future adjustments, which could be material. Nothing contained in this Monthly Operating Report shall constitute a waiver of any of the Debtor's rights or an admission with respect to its Chapter 11 proceedings. The Debtor reserves all rights to amend, modify or supplement this Monthly Operating Report.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-1

SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS ¹

	BANK ACCOUNTS										CURRENT PERIOD					FILING TO DATE
	Business checking (Capital One)		Business money market (Capital One)		Certificate of deposit (Capital One)		Investment (Wilmington Trust)		Cash reserves (Fidelity)		ACTUAL		PROJECTED 2			ACTUAL		PROJECTED 3
Account number ending in		0542		9462		4101		6389		2370
Beginning cash balance		656,266		361		53,427		-		0		710,054		655,097			91,158		91,158
RECEIPTS
Revenue collections		126,737		-		-		-		-		126,737		314,489			262,720		450,472
Loans and advances		1,000,000		-		-		-		-		1,000,000		1,500,000			2,500,000		3,000,000
Sweeps from / (to) other accounts		-		-		-		-		-		-		-			-		-
Transfers from other accounts		-		-		-		-		-		-		-			-		-
Proceeds from sale of assets		-		-		-		-		-		-		-			-		-
Other collections		6,120		0		-		-		-		6,120		-			6,199		79
TOTAL  RECEIPTS		1,132,857		0		-		-		-		1,132,857		1,814,489			2,768,918		3,450,551
DISBURSEMENTS
Payroll and payroll taxes		234,106		-		-		-		-		234,106		261,628			575,793		603,315
Sales commissions		20,680		-		-		-		-		20,680		20,000			34,410		33,730
Employee benefits		28,898		-		-		-		-		28,898		54,642			61,351		87,095
Employee travel and entertainment		19,572		-		-		-		-		19,572		50,151			45,922		76,501
Research and development services		-		-		-		-		-		-		42,437			-		42,437
Inventory purchases		77,305		-		-		-		-		77,305		117,342			85,889		125,927
Outside services		15,636		-		-		-		-		15,636		14,919			26,166		25,449
Marketing expense		-		-		-		-		-		-		37,971			-		37,971
Reimbursement expense		2,861		-		-		-		-		2,861		55,780			2,861		55,780
Investor relations		1,282		-		-		-		-		1,282		3,323			1,282		3,323
Insurances		15,488		-		-		-		-		15,488		-			62,675		47,187
Information technology		56,298		-		-		-		-		56,298		21,087			56,298		21,087
Supplies		-		-		-		-		-		-		21,941			-		21,941
Utilities		8,292		-		-		-		-		8,292		2,850			8,452		3,010
Licensing fees		871		-		-		-		-		871		2,526			871		2,526
Professional fees, ordinary course		22,449		-		-		-		-		22,449		54,993			22,449		54,993
Board of Directors fees		-		-		-		-		-		-		14,919			-		14,919
Excise taxes		-		-		-		-		-		-		20,823			5,692		26,515
All other operating disbursements		49,799		-		-		-		-		49,799		62,701			77,120		144,979
Bank fees		631		-		-		-		-		631		10,000			1,216		10,585
Income and business taxes		3,267		-		-		-		-		3,267		31,200			12,159		40,092
Interest, DIP loan new money		-		-		-		-		-		-		32,143			-		32,143
Interest, DIP loan pre-petition roll-up		-		-		-		-		-		-		-			-		-
Fees, DIP loan		-		-		-		-		-		-		22,500			67,500		90,000
Professional fees, restructuring		392,989		-		-		-		-		392,989		805,817			562,990		975,818
U.S. Trustee fees		-		-		-		-		-		-		-			-		-
Transaction fees		-		-		-		-		-		-		-			-		-
Vendor deposits		25,000		-		-		-		-		25,000		120,000			55,000		150,000
Critical-vendor payments		133,706		-		-		-		-		133,706		200,000			360,197		426,491
Priority claims		-		-		-		-		-		-		-			-		-
KEIP/KERP		-		-		-		-		-		-		-			-		-
All other (sources) / uses		-		-		-		-		-		-		-			-		-
Transfers to other accounts		-		-		-		-		-		-		-			-		-
TOTAL  DISBURSEMENTS		1,109,132		-		-		-		-		1,109,132		2,081,694			2,126,297		3,153,816
NET CASH FLOW		23,725		0		-		-		-		23,725		(267,205	)		642,622		296,735
Ending cash balance	$	679,991	$	361	$	53,427	$	-	$	0	$	733,779	$	387,892		$	733,779	$	387,892

DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES
TOTAL DISBURSEMENTS  (January 27, 2016 through March 31, 2016)	2,126,297
SUBTRACT: TRANSFERS TO DEBTOR IN POSSESSION  ACCOUNTS	0
ADD: ESTATE DISBURSEMENTS MADE BY OUTSIDE SOURCES  (i.e. from escrow accounts)	0
TOTAL DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES	2,126,297

1. The accounting systems are not primarily designed to produce reports that are consistent with the requirements of the Office of the United States Trustee. The numbers presented in the cash flow are subject to change as additional information is made available. The information contained herein is provided to fulfill the requirements of the Office of the United States Trustee. All information contained herein is unaudited and subject to future adjustments.

2. The figures in the Projected column reflect the DIP Budget exhibited in the Final Order Under Sections 105, 361, 362, 363(c), 363(e), 364(c)(1), 364(c)(2), 364(c)(3), 364(d)(1), 364(e), and 507 of the Bankruptcy Code and Bankruptcy Rules 2002, 4001 and 9014 (I) Authorizing Debtor to Obtain Postpetition Financing; (II) Authorizing Debtor to Use Cash Collateral; (III) Granting Adequate Protection to Prepetition Secured Parties; and (IV) Granting Related Relief, entered on March 9, 2016.

3. The figures in the Projected column reflect the sum of actual results from the filing to date through February 29, 2016, and the DIP Budget exhibited in the Final Order as mentioned above from March 1 through March 31, 2016.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-1a

BANK ACCOUNTS ¹

Bank name	Account type	Account number	Period-end bank balance
Capital One Bank (USA) N.A.	Business checking	ending in 0542		758,378.57
Capital One Bank (USA) N.A.	Business money market	ending in 9462		361.42
Capital One Bank (USA) N.A.	Certificate of deposit for Maryland Board of Pharmacy	ending in 4101		53,427.00
Wilmington Trust Corporation 2	Investment	ending in 6389		0.00
FMR LLC (Fidelity) 3	Cash reserves	ending in 2370		0.15
TOTAL BANK BALANCE				812,167.14

1. An attestation regarding the Debtor's bank statements and bank-account reconciliations follows this schedule.

2. Due to this account's balance being zero as of the petition date and as of the end of the Reporting Period, no reconciliation is provided for this account. This account was closed on Tuesday, March 9, 2016.

3. In accordance with the request of the Office of the United States Trustee, the Debtor requested this account to be closed on Tuesday, March 8, 2016.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-1a

ATTESTATION REGARDING BANK ACCOUNTS

The above-captioned Debtor hereby submits this attestation regarding disbursement journals and bank-account reconciliations in lieu of providing copies of bank statements and account reconciliations.

I attest that each of the bank accounts listed in the preceding schedule is reconciled to monthly bank statements. The Debtor's standard practice is to ensure that each bank account is reconciled to monthly bank statements for each calendar month within 20 days after month end.

/s/ David E. Jorden	April 20, 2016
Signature of authorized individual	Date
David E. Jorden	Acting CEO and Acting CFO
Printed name of authorized individual	Title of authorized individual

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-1b

SCHEDULE OF PROFESSIONAL FEES AND EXPENSES PAID

This schedule is to include all retained professional payments from case inception to current month.

		Amount			Check		Period amount paid				Case-to-date amount paid
Payee	Period covered	approved		Payor	#/EFT	Date paid	Fees		Expenses		Fees		Expenses
Winter Harbor LLC	2/22/16 - 2/28/16		49,476.48	Nuo Therapeutics, Inc.	EFT	3/7/2016		46,435.50		3,040.98
Winter Harbor LLC	2/29/16 - 3/6/16		37,199.53	Nuo Therapeutics, Inc.	EFT	3/11/2016		34,790.50		2,409.03
Winter Harbor LLC	3/7/16 - 3/13/16		42,735.59	Nuo Therapeutics, Inc.	EFT	3/18/2016		38,920.00		3,815.59
Winter Harbor LLC	3/14/16 - 3/20/16		38,009.71	Nuo Therapeutics, Inc.	EFT	3/29/2016		35,603.00		2,406.71
Winter Harbor LLC	3/21/16 - 3/27/16		33,069.34	Nuo Therapeutics, Inc.	EFT	3/31/2016		31,079.50		1,989.84
			200,490.65					186,828.50		13,662.15		348,647.00		21,844.44
Dentons US LLP	None		-	Nuo Therapeutics, Inc.	None	None		-		-		-		-
Ashby & Geddes, P.A.	None		-	Nuo Therapeutics, Inc.	None	None		-		-		-		-
Gordian Group, LLC	None		-	Nuo Therapeutics, Inc.	None	None		-		-		-		-
Epiq Bankruptcy Solutions, LLC	1/27/16 - 2/29/16		70,771.41	Nuo Therapeutics, Inc.	EFT	3/11/2016		26,971.41		43,800.00		26,971.41		43,800.00
Pepper Hamilton LLP	None		-	Nuo Therapeutics, Inc.	None	None		-		-		-		-
Robbins, Salomon & Patt, Ltd.	None		-	Nuo Therapeutics, Inc.	None	None		-		-		-		-
			271,262.06					213,799.91		57,462.15		375,618.41		65,644.44

Professional	Role	Notes
Winter Harbor LLC	Debtor's Chief Restructuring Officer and additional personnel
Dentons US LLP	Debtor's counsel, lead
Ashby & Geddes, P.A.	Debtor's counsel, local
Gordian Group, LLC	Debtor's investment banker and related services
Epiq Bankruptcy Solutions, LLC	Debtor's noticing, claims and balloting agent
Pepper Hamilton LLP	Counsel to the Official Committee of Unsecured Creditors
Robbins, Salomon & Patt, Ltd.	Counsel to the Ad Hoc Equity Committee

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-2

STATEMENT OF OPERATIONS (UNAUDITED) ¹

Line item	Current period			Filing to date
Revenue
Sales, Aurix		40,430			163,670
Sales, Angel		(13,328	)		54,463
Royalties		101,200			297,364
License fees		33,531			72,471
Other sales		-			-
Total revenue		161,833			587,968
Cost of sales
Cost of goods sold, Aurix		59,921			118,793
Cost of goods sold, Angel		47,150			97,038
Cost of royalties		13,083			28,277
Cost of license fees		(313	)		(313	)
Other cost of sales		893			8,489
Total cost of sales		120,734			252,284
Gross profit		41,100			335,684
Operating expenses
Employee compensation and benefits		281,682			629,989
Insurance		25,983			55,492
Rent		16,299			40,470
Travel and entertainment		15,886			36,403
Depreciation and amortization		38,829			83,939
Selling and marketing expense		10,568			67,360
Research and development expense		90,503			135,807
Professional fees		53,558			99,882
Board of Directors fees		15,417			33,320
Other operating expenses 2		62,106			130,759
Total operating expenses		610,831			1,313,421
Operating profit		(569,731	)		(977,737	)
Non-operating expenses
Interest expense / (income)		264,030			507,792
Reorganization expense / (income) 2		1,100,678			2,083,936
Loss / (gain) on asset disposal		(2,040	)		-
Other non-operating expense / (income)		-			-
Income-tax expense		4,896			4,896
Total non-operating expenses		1,367,563			2,596,623
NET INCOME		(1,937,295	)		(3,574,360	)

1. The accounting systems are not primarily designed to produce reports that are consistent with the requirements of the Office of the United States Trustee. The information contained herein is provided to fulfill the requirements of the Office of the United States Trustee. All information contained herein is unaudited and subject to future adjustments.

2. See the continuation sheet following Schedule MOR-2 for additional detail regarding these line items.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-2 CONTINUATION SHEET

STATEMENT OF OPERATIONS (UNAUDITED) ¹

Line item	Current period			Filing to date
Other operating expenses
Other services		-			426
Investor services		1,356			5,141
Information technology		12,989			28,120
Temporary labor		-			-
Repairs and maintenance		-			-
Supplies		417			538
Office expense 2		(40,070	)		(14,734	)
State and local taxes		8,524			15,674
Business-development expense		-			-
Bad-debt expense		(5,535	)		(5,535	)
Dues, subscriptions and fees		84,035			100,637
Miscellaneous expense		390			492
Total other operating expenses		62,106			130,759
Reorganization expense / (income) 3
Professional fees, Debtor's Chief Restructuring Officer		172,758			397,549
Professional fees, Debtor's counsel, lead		448,968			776,744
Professional fees, Debtor's counsel, local		78,277			172,277
Professional fees, Debtor's investment banker and related services		50,117			111,826
Professional fees, Debtor's claims and noticing agent		113,032			132,431
Professional fees, DIP lender's counsel, lead and local		20,027			140,109
Professional fees, Unsecured Creditors' Committee counsel		129,000			258,000
Professional fees, Ad Hoc Equity Committee counsel		85,000			85,000
U.S. Trustee fees		3,500			10,000
Total reorganization expense		1,100,678			2,083,936

1. The accounting systems are not primarily designed to produce reports that are consistent with the requirements of the Office of the United States Trustee. The numbers presented in this schedule are subject to change as additional information is made available. The information contained herein is provided to fulfill the requirements of the Office of the United States Trustee. All information contained herein is unaudited and subject to future adjustments.

2. The credit amount in this line item reflects a reclassification of freight costs to cost of goods sold.

3. Several of these expenses are estimated in the case where invoices have not been received.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-3

BALANCE SHEET (UNAUDITED) ¹

Line item	Current period			As of petition date
ASSETS
Current assets
Cash and cash equivalents		733,779			94,558
Accounts receivable		836,717			1,237,057
Intercompany receivable		14,838,499			14,593,348
Other receivables		814,267			474,489
Inventory		196,882			254,764
Deposits		399,496			478,564
Prepaid expenses		635,425			727,665
Deferred costs, current portion		1,113,887			1,091,387
Total current assets		19,568,952			18,951,831
Property, plant and equipment 2
Angel machines		225,493			225,493
Aurix centrifuges		924,970			924,970
Computer and office equipment		113,842			113,842
Furniture and fixtures		40,849			40,849
Production equipment		307,851			307,851
Leasehold improvements		32,131			32,131
Software		523,571			523,571
Less: Accumulated depreciation		(1,213,171	)		(1,119,749	)
Net property, plant and equipment		955,537			1,048,959
Other assets
Deferred costs, long-term portion		2,182,772			2,379,339
Investment, Aldagen 2		31,753,381			31,753,381
Intangible assets, net of accumulated amortization 2		1,782,000			1,830,059
Other long-term assets		50,178			11,986
Total other assets		35,768,331			35,974,765
TOTAL ASSETS		56,292,820			55,975,555
LIABILITIES AND OWNERS' EQUITY
Liabilities not subject to compromise
Accounts payable		647,442			-
Accrued compensation and benefits		32,492			-
Accrued expenses		1,127,820			-
Accrued taxes		33,495			-
Accrued interest		33,147			-
Customer deposits		371,333			-
Debtor-in-possession financing		2,500,000			-
Convertible debt, net of original issue discount		-			-
Deferred revenue		938,860			-
Derivative liabilities		-			-
Other long-term liabilities		389,314			-
Total liabilities not subject to compromise		6,073,903			-
Liabilities subject to compromise 3
Accounts payable		1,455,903			2,293,463
Accrued compensation and benefits		889,158			950,283
Accrued expenses		874,418			735,733
Accrued taxes		20,120			50,352
Accrued interest		4,529,645			4,529,645
Customer deposits		-			329,145
Debtor-in-possession financing		-			-
Convertible debt, net of original issue discount		1,181,446			981,554
Deferred revenue		-			1,072,103
Derivative liabilities		2,597,930			2,597,930
Other long-term liabilities		-			207,892
Total liabilities subject to compromise		11,548,621			13,748,099
Shareholders' equity
Mezzanine equity		500,000			500,000
Common stock		405,427			405,427
Additional paid-in capital		125,996,258			125,979,057
Retained earnings / (losses), pre-petition 3		(84,657,028	)		(84,657,028	)
Retained earnings / (losses), post-petition		(3,574,360	)		-
Total shareholders' equity		38,670,297			42,227,456
TOTAL LIABILITIES AND OWNERS' EQUITY		56,292,820			55,975,555

1. The accounting systems are not principally designed to produce reports that are consistent with the requirements of the Office of the United States Trustee. The numbers presented in this schedule are subject to change as additional information is made available. The information contained herein is provided to fulfill the requirements of the Office of the United States Trustee. All information contained herein is unaudited and subject to future adjustments.

2. With respect to the book value of property, plant and equipment, the subsections of Accounting Standards Codification 360-10 “Property, Plant, and Equipment—Overall” published by the Financial Accounting Standards Board related to impairment or disposal of long-lived assets mandate that long-lived assets, such as property, plant and equipment, and purchased intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Although an impairment test has not yet been performed for the fiscal year ended December 31, 2015, the Debtor expects an asset impairment could be required in one or more asset categories.

3. Pre-petition liabilities and retained earnings continue to be adjusted monthly based on actual pre-petition invoices received and reconciled post-petition.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-4

STATUS OF POST-PETITION TAXES

Line item	Beginning liability			Amount withheld, accrued, and expensed			Amount paid			Date paid	Check #, EFT, or Other	Ending liability
Employee-related taxes
Federal tax		71			75,534			(75,534	)	Various	ACH		71
State tax		14			8,067			(8,064	)	Various	ACH		17
City tax		0			107			(107	)	Various	ACH		0
School-district tax		0			101			(101	)	Various	ACH		0
Subtotal, employee-related taxes		86			83,809			(83,806	)				88
Income and business taxes
Sales tax		24,794			1,796			(5,792	)	Various	Transferred to A/P		20,798
Franchise tax		6,774			5,833			-		None	None		12,608
Income tax		-			4,896			-		None	None		4,896
All other taxes		-			-			-		None	None		-
Subtotal, income and business taxes		31,568			12,525			(5,792	)				38,302
Taxes included in accounts payable		2,101			6,106			(2,018	)	Various	ACH		6,189
TOTAL TAXES		33,755			102,440			(91,616	)				44,579
Less: Taxes included in accounts payable		(2,101	)		(6,106	)		2,018		None	None		(6,189	)
Less: Taxes included in other long-term liabilities		-			(4,896	)		-		None	None		(4,896	)
TOTAL ACCRUED TAXES		31,654			91,438			(89,598	)				33,494

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-4

ATTESTATION REGARDING STATUS OF POST-PETITION TAXES

The above-captioned Debtor hereby submits this attestation regarding the status of post-petition taxes in lieu of providing tax returns and detailed records of paid or unpaid taxes by type and entity.

I hereby certify, to the best of my knowledge, that: (1) all federal, state and local post-petition taxes and estimates due and owing for the period indicated above for the Debtor have been paid or that any remaining balance dues are de minimis; and (2) to the extent that tax returns have not been submitted, an extension has been either obtained or requested from the appropriate state or federal agency, or the Debtor is in the process of obtaining or requesting such extension from the appropriate state or federal agency.

/s/ David E. Jorden	April 20, 2016
Signature of authorized individual	Date
David E. Jorden	Acting CEO and Acting CFO
Printed name of authorized individual	Title of authorized individual

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-4

STATUS OF UNPAID POST-PETITION DEBTS ¹

	Days Outstanding
Line item	Current		1-30 3		31-60		61-90			91-120		Over 120		Totals
Accounts payable 2		81,895		515,052		52,180		(1,685	)		-		-		647,442
Accrued compensation and benefits		32,492		-		-		-			-		-		32,492
Accrued expenses		1,127,820		-		-		-			-		-		1,127,820
Accrued taxes		33,495		-		-		-			-		-		33,495
Accrued interest		33,147		-		-		-			-		-		33,147
Customer deposits		371,333		-		-		-			-		-		371,333
Debtor-in-possession financing		2,500,000		-		-		-			-		-		2,500,000
Convertible debt, net of original issue discount		-		-		-		-			-		-		-
Deferred revenue		938,860		-		-		-			-		-		938,860
Derivative liabilities		-		-		-		-			-		-		-
Other long-term liabilities		389,314		-		-		-			-		-		389,314
Totals		5,508,356		515,052		52,180		(1,685	)		-		-		6,073,903

1. All information contained herein is unaudited and subject to future adjustments. Certain debts payable pursuant to orders of the Bankruptcy Court are reflected as current for the purposes of this schedule. All post-petition debts other than aged accounts payable are assumed to be current.

2. Amounts in this line item represent open and outstanding trade vendor invoices, aged based on invoice due date, that have been entered into the Debtor's accounts payable system. These amounts do not include any payables based on accruals for goods provided and/or services performed but for which invoices have not been received. The Debtor expects to pay all amounts not listed as "Current" as soon as practicable. This note is provided in place of a list of aged accounts payable.

3. This balance includes $478,771 of Debtor's professional fees, which will be paid once a Certificate of No Objection is filed with the Bankruptcy Court for each professional's fee application.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-5

ACCOUNTS RECEIVABLE RECONCILIATION AND AGING ^*

	Days Outstanding
Line item	Current			1-30			31-60			61-90			Over 90			Totals
Accounts receivable		(60,771	)		104,428			139,371			330,124			403,751			916,903
Less: Allowance for doubtful accounts		-			-			-			-			(80,186	)		(80,186	)
Totals		(60,771	)		104,428			139,371			330,124			323,565			836,717
		-7.3	%		12.5	%		16.7	%		39.5	%		38.7	%		100.0	%
Reconciliation of accounts receivable, trade
Accounts receivable, net at the beginning of the reporting period																	1,427,261
Add: Amounts billed during the period																	89,274
Subtract: Amounts collected during the period																	(107,114	)
Subtract: Change in allowance for doubtful accounts																	5,535
Adjustment: Reconciliation of net receivable due from Bioprod Biomedicinski Produkti d.o.o.																	(519,507	)
Adjustment: Deferred revenue applied to accounts receivable																	(60,771	)
Other adjustments																	2,040
Accounts receivable at the end of the reporting period																	836,717

* All information contained herein is unaudited and subject to future adjustments.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: March 1 - March 31, 2016

MOR-5a

DEBTOR QUESTIONNAIRE

#	Line item	Yes	No
1	Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.		ü
2	Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.		ü
3	Have all post-petition tax returns been timely filed? If no, provide an explanation below.	ü
4	Are workers' compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.	ü
5	Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s).		ü

Explanations

1	None required
2	None required
3	None required
4	None required
5	None required